Novo Nordisk's Dual Challenge: Building Production Muscle While Proving Pipeline Might

Novo Nordisk stock down 47% as investors eye €1B Italy plant expansion and pivotal Phase 3 CagriSema data at ADA; Medicare Wegovy access from July.

Novo Nordisk enters June with two heavyweight narratives in play, each addressing a different vulnerability that has hammered its stock down by nearly half over the past year. On one hand, the Danish drugmaker has secured a multi-billion-euro expansion of its Italian manufacturing site in Anagni, a move aimed at easing the chronic supply bottlenecks that have plagued its GLP-1 franchise. On the other, it is about to unveil pivotal Phase 3 data for CagriSema at the American Diabetes Association meeting, a clinical moment that will test whether its next-generation obesity pipeline can offset mounting pricing pressure—especially as Medicare opens its doors to Wegovy from July.

The shares closed at €36.40 on Wednesday and edged up to €36.59 on Thursday, a modest 0.55% gain. But the broader trend remains grim: the stock is still 47.8% below its 52-week high of €70.13, with a year-to-date deficit of 18.1% and a 12-month slide of 42.3%. The confidence-sapping gap between demand for weight-loss drugs and Novo’s ability to supply them has been a central investor concern, and the Anagni commitment speaks directly to that.

Italy’s Economic Minister Adolfo Urso met with Novo Nordisk Italy vice-president Jens Pii Olesen and special commissioner Francesco Rocca to confirm the plan. The factory investment exceeds €1 billion and is expected to create around 400 direct jobs. Anagni will be transformed into a development hub for new obesity therapies, building on the acquisition of three production sites from Novo Holdings in December 2024 as part of the Catalent deal. The message from management at the time was that the added capacity would expand manufacturing “at scale and speed.” Yet the stock’s trajectory shows investors remain unconvinced that Novo can close the supply gap before rivals like Eli Lilly and Roche catch up.

The clinical calendar now offers a potential counterpunch. From June 5 to 8, 2026, Novo Nordisk will present 40 abstracts at the ADA Scientific Sessions in New Orleans. The spotlight falls on the Phase 3 REIMAGINE programme for CagriSema, a once-weekly injection combining cagrilintide and semaglutide, which must demonstrate superior blood-sugar control and weight loss in type 2 diabetes. Also on the docket are Phase 2b data for Zenagamtid, a dual GLP-1/amylin receptor agonist that could differentiate Novo’s pipeline, and fresh evidence on Ozempic and Wegovy in cardiometabolic disease. The company will host an R&D investor event on June 7 at 6:30 p.m. local time to contextualise the results. CagriSema has been under FDA review since December 2025; a decision is expected in the fourth quarter of 2026, with a potential launch in early 2027.

Just weeks later, a commercial catalyst arrives. From July 1, 2026, eligible Medicare beneficiaries with obesity will gain access to Wegovy—both injection and tablet forms—for a monthly copay of $50. The move breaks a longstanding federal prohibition on Medicare covering weight-loss drugs. Novo and Eli Lilly have agreed on a net price of $245 per month, far below list prices that exceed $1,000. The programme runs until December 31, 2027 and could open the door to millions of new patients. But the trade-off is clear: higher volume, lower realised prices.

Indeed, the pricing headwinds are formidable. Novo Nordisk expects revenue and operating profit to decline by 5% to 13% in 2026, driven by lower US realised prices, reduced Medicaid reimbursements for obesity treatments, and the impact of a most-favoured-nation pricing agreement. The loss of semaglutide exclusivity in several international markets compounds the pressure. That is why the ADA data carry so much weight: strong clinical results can reinforce the pipeline narrative and give investors a reason to look past near-term margin erosion.

Meanwhile, the company continues its share buyback programme, which authorises up to 15 billion Danish kroner and began on February 4. As of May 29, Novo had repurchased 17.89 million B-shares for 4.71 billion kroner. The buyback offers a floor of sorts, but the stock’s fate rests on a delicate interplay between manufacturing execution, clinical credibility, and the commercial realities of a market that is simultaneously expanding and tightening.